Comparing the current results to its competitors, Cytosorbents reported Revenue increase in the 2 quarter 2026 by 9.29 % year on year, while most of its competitors have experienced contraction in revenues by -7.84 %, achieved in the same quarter.
Cytosorbents Corporation, slower than the average decrease reported by the company's competitors of -34.13 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -34.13 %
Cytosorbents's Comment on Competition and Industry Peers
The cardiovascular surgery market includes several competitors and products. Brilinta competes with Plavix (clopidogrel, Bristol-Myers Squibb, Sanofi) and Effient (prasugrel, Daiichi Sankyo, Eli Lilly). Generic ticagrelor has been available in the U.S. since mid-2025. In blood purification therapies aimed at cytokine reduction, competitors include Oxiris and SepteX (Vantive), PMMA (Toray), HA330 and HA380 (Jafron), therapeutic plasma exchange (TPE) from multiple manufacturers, Efferon-CT and Efferon-LPS (Efferon), and EMIC-2 (Fresenius Medical Care). CytoSorb is the only therapy approved in the European Union for removal of ticagrelor and rivaroxaban (Xarelto®, Janssen, Bayer) during cardiac surgery. One competitor voluntarily withdrew its product from FDA consideration due to safety concerns, potentially reducing competitive pressure. The company's products employ a different modality and may be viewed more favorably. Currently, no therapies are specifically approved for cytokine removal except ECOS-300CY for ex vivo organ perfusion. VetResQ utilizes polymer technology comparable to CytoSorb. Litigation among competitors is frequent, involving multiple lawsuits and settlements that impact patent portfolios and competitive dynamics.
Competitors identified include Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Efferon, Eli Lilly, Fresenius Medical Care, Jafron, Janssen, Sanofi, Toray, and Vantive.
With revenue growth of 9.29 % within Overall company, Cytosorbents Corporation achieved improvement in market share, within Overall company to approximately 0.16 %. << More on CTSO Market Share.
*Market share is calculated based on total revenue.
July 30, 2024
Advancements in Healthcare and Digital Media: The Strategic Moves of CytoSorbents and ZoomerMediaIn a rapidly evolving landscape of healthcare and digital media, two companies have made significant strides: CytoSorbents Corporation and ZoomerMedia. The recent moves by these firms ranging from the launch of a unified website support to regulatory approvals demonstrate innovative approaches to enhance their brand presence and operational capacity. CytoSorbents: A Unified Digital Presence to Save LivesCytoSorbents Corporation, a leader in blood purification technology, has revamped its online presence with a newly redesigned and unified company and product website. The new design highlights the company s miss...
June 25, 2024
ZoomerMedia Enhances Digital Network by Acquiring MobileSyrup.com from Blue Ant Media, Canada’s Premier Tech News SourceToronto, Canada In a strategic move to advance its digital footprint, ZoomerMedia Limited has officially announced the acquisition of MobileSyrup.com, a leading Canadian technology news platform, from Blue Ant Media. This acquisition significantly enriches the Zoomer Digital Network’s portfolio, greatly expanding its reach and content offerings in the highly competitive digital media landscape.MobileSyrup.com has established itself over the years as Canada’s most trusted news source for all things related to mobile technology, offering detailed reports, expert analysis, and comprehen...
December 28, 2023
Septic shock remains a significant healthcare burden worldwide, with high mortality rates and limited treatment options. The recent advancements in hemoadsorption therapy using the CytoSorb® extracorporeal hemoperfusion device have shown promising results in improving patient outcomes. This article presents an extensive review of two pivotal studies, namely CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation and CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation. We delve into the implications, clinical significance, and potential future impact of these findings in the management of septic shock.Ba...
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
ICU Medical Inc's business model focuses on the development, manufacture, and sale of innovative medical devices and solutions for critical care settings.
Haemonetics Corporation's business model revolves around providing innovative solutions and technologies for the collection, processing, and management of blood and its components.
Fresenius Medical Care AG & Co. KGaA is a global healthcare company that specializes in providing services and products for patients with chronic kidney failure. Their business model focuses on offering a comprehensive range of innovative dialysis products, services, and patient care for individuals suffering from kidney-related issues. Through their network of clinics, dialysis centers, and manufacturing sites, they aim to provide high-quality renal care and improve the lives of patients worldwide.
Sources:
Cytosorbents Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cytosorbents Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
